Icagen, Inc. has entered into a worldwide collaboration and licensing agreement with Pfizer for the discovery, development and commercialization of ion channel-focused therapeutics for pain and related disorders. The two companies will combine resources to identify compounds that target three ion channels. Pfizer will fund all aspects of the collaboration including the research and preclinical development efforts at Icagen and will have exclusive worldwide rights to commercialize products that r...